Dynamic control of Th2 cell responses by STAT3 during allergic lung inflammation in mice

被引:26
作者
Lim, Hoyong [1 ]
Cho, Minkyoung [1 ]
Choi, Garam [1 ]
Na, Hyeongjin [1 ]
Chung, Yeonseok [1 ]
机构
[1] Seoul Natl Univ, Pharmaceut Sci Res Inst, Coll Pharm, Lab Immune Regulat, Seoul 151742, South Korea
基金
新加坡国家研究基金会;
关键词
STAT3; Allergic asthma; Th2; cell; Th17; Th1; AIRWAY INFLAMMATION; T(H)17 CELLS; T-BET; TH17; RESPONSES; DOUBLE-BLIND; ASTHMA; EXPRESSION; HELPER; CYTOKINE; MODERATE;
D O I
10.1016/j.intimp.2015.03.051
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Signal transducer and activator of transcription (STAT) family molecules play essential roles during the differentiation of helper T cells from naive precursors. Although the role of STAT3 in driving Th17 cell polarization has been well established, its role on Th2 responses to allergens remains incompletely understood. By employing T cell-specific STAT3 deficient mice, we demonstrate that STAT3 in T cells plays diverse role on Th2 cells depending on their locations in an animal model of allergic asthma. In the bronchial lymph nodes, STAT3-deficient T cells produced significantly reduced levels of Th2 cytokines. The frequencies of Th2 cells among CD4(+) T cells in the lung were comparable between STAT3-sufficient and STAT3-deficient T cells. By contrast, STAT3-deficient T cells in the airway exhibited significantly enhanced production of Th2 cell cytokines compared to STAT3-sufficient T cells. Interestingly, a major population of IL-4/5 producers among STAT3-deficient T cells in the airway co-produced IFN gamma. The frequency of Th17 cells was significantly diminished whereas that of Th1 cells was increased in all the lung-associated tissues. Our results demonstrate the dynamic and opposing roles of STAT3 during the development of Th2 cells from bronchial lymph nodes to the airway and propose the need of careful consideration on STAT3-targeting approaches for the treatment of lung diseases. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:846 / 853
页数:8
相关论文
共 59 条
[1]   T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells [J].
Afkarian, M ;
Sedy, JR ;
Yang, J ;
Jacobson, NG ;
Cereb, N ;
Yang, SY ;
Murphy, TL ;
Murphy, KM .
NATURE IMMUNOLOGY, 2002, 3 (06) :549-557
[2]   TH17 Cells in Asthma and COPD [J].
Alcorn, John F. ;
Crowe, Christopher R. ;
Kolls, Jay K. .
ANNUAL REVIEW OF PHYSIOLOGY, 2010, 72 :495-516
[3]   Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease [J].
Anderson, Gary P. .
LANCET, 2008, 372 (9643) :1107-1119
[4]   How do corticosteroids work in asthma? [J].
Barnes, PJ ;
Adcock, IM .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (05) :359-370
[5]   Intermittent inhaled corticosteroids in infants with episodic wheezing [J].
Bisgaard, H ;
Hermansen, MN ;
Loland, L ;
Halkjaer, LB ;
Buchvald, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (19) :1998-2005
[6]   Efficacy of soluble IL-4 receptor for the treatment of adults with asthma [J].
Borish, LC ;
Nelson, HS ;
Corren, J ;
Bensch, G ;
Busse, WW ;
Whitmore, JB ;
Agosti, JM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (06) :963-970
[7]   IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? [J].
Bullens, Dominique M. A. ;
Truyen, Els ;
Coteur, Liesbeth ;
Dilissen, Ellen ;
Hellings, Peter W. ;
Dupont, Lieven J. ;
Ceuppens, Jan L. .
RESPIRATORY RESEARCH, 2006, 7 (1)
[8]   Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma [J].
Busse, William W. ;
Holgate, Stephen ;
Kerwin, Edward ;
Chon, Yun ;
Feng, JingYuan ;
Lin, Joseph ;
Lin, Shao-Lee .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 188 (11) :1294-1302
[9]   Advances in immunology - Asthma [J].
Busse, WW ;
Lemanske, RF .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (05) :350-362
[10]   Pharmacology of airway inflammation in asthma and COPD [J].
Caramori, G ;
Adcock, I .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2003, 16 (05) :247-277